ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance

Tuesday, February 27, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

ANI Pharmaceuticals, Inc. and Subsidiaries

Table 6: Historical Adjusted non-GAAP EBITDA Calculation and US GAAP to Non-GAAP Reconciliation

(unaudited, in thousands)

Year Ended December 31,

2015

2014

2013

   Net Income from Continuing Operations

$15,375

$28,747

$   106

Add back

   Interest expense, net

11,008

787

467

   Other (expense)/income, net

(41)

(160)

305

   Provision/(benefit) for income taxes

6,358

(9,368)

20

   Depreciation and amortization

6,900

3,878

1,110

Add back

   Stock-based compensation

3,856

3,423

36

   Merger-related expenses

-

-

5,468

         Adjusted non-GAAP EBITDA

$43,456

$27,307

$7,512



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store